Eli Lilly is pouring its massive cash reserves into artificial intelligence drug discovery, launching an internal platform that CEO Dave Ricks describes as an 'App Store' for biotech scientists. The Indianapolis-based pharma invested in a data center powered by 1,016 Nvidia Blackwell chips and partnered with roughly 100 smaller biotech companies, trading AI model access for their research data.

The company's war chest reached $7.3bn in cash and liquid assets by end-2025, a 121% increase year-over-year. This positions Lilly to diversify beyond its blockbuster weight-loss drugs like Mounjaro and Foundayo before patent expirations hit in the 2030s. The strategy includes 11 acquisitions this year alone and a $2bn licensing deal with Insilico Medicine for a potential GLP-1 drug.

Partnerships span from Charles River Laboratories to a San Francisco lab where Lilly scientists work alongside Nvidia engineers. Ricks acknowledged AI's limitations, noting it remains unproven for actual drug development despite tech sector ambitions. The company signed about 20 AI licensing deals, more than any other pharmaceutical firm as of May.

With $1.1tn market capitalization and Q1 earnings of $8.26 per share, Lilly leads its rival Novo Nordisk with 1.6 million US weight-loss prescriptions versus 1.1 million. A Medicare pilot program launching in July could boost sales volume significantly, offsetting any marginal pricing reductions from government reimbursement.